Market Closed -
Nasdaq
16:00:00 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
5.2
USD
|
-4.41%
|
|
+1.96%
|
-33.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
293.3
|
608.9
|
201.9
|
72.61
|
202.6
|
139
|
-
|
-
|
Enterprise Value (EV)
1 |
293.3
|
608.9
|
111.8
|
72.61
|
202.6
|
139
|
139
|
139
|
P/E ratio
|
-3.68
x
|
-5.96
x
|
-2.36
x
|
-0.48
x
|
-1.34
x
|
-1.41
x
|
-1.56
x
|
-3.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
148
x
|
40.3
x
|
8.6
x
|
4.88
x
|
20.4
x
|
49.6
x
|
4.33
x
|
0.92
x
|
EV / Revenue
|
148
x
|
40.3
x
|
8.6
x
|
4.88
x
|
20.4
x
|
49.6
x
|
4.33
x
|
0.92
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-10,031,912
x
|
-2,003,747
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
6.74
x
|
2.37
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,244
|
5,612
|
6,195
|
20,226
|
26,007
|
26,728
|
-
|
-
|
Reference price
2 |
69.10
|
108.5
|
32.60
|
3.590
|
7.790
|
5.200
|
5.200
|
5.200
|
Announcement Date
|
20-03-05
|
21-03-04
|
22-03-15
|
23-03-02
|
24-03-27
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.982
|
15.09
|
23.49
|
14.88
|
9.936
|
2.8
|
32.08
|
151.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-77.74
|
-82.3
|
-99.42
|
-135.9
|
-129
|
-119.1
|
-110.2
|
-45.2
|
Operating Margin
|
-3,922.35%
|
-545.27%
|
-423.28%
|
-913.12%
|
-1,298.19%
|
-4,252.68%
|
-343.52%
|
-29.9%
|
Earnings before Tax (EBT)
1 |
-75.44
|
-84.04
|
-86.56
|
-94.65
|
-164.6
|
-128
|
-120.1
|
-54.2
|
Net income
1 |
-75.44
|
-84.04
|
-86.56
|
-94.65
|
-164.6
|
-124.9
|
-120.1
|
-54.2
|
Net margin
|
-3,806.16%
|
-556.8%
|
-368.52%
|
-636.12%
|
-1,656.34%
|
-4,461.25%
|
-374.34%
|
-35.85%
|
EPS
2 |
-18.80
|
-18.20
|
-13.80
|
-7.490
|
-5.810
|
-3.688
|
-3.344
|
-1.493
|
Free Cash Flow
|
-
|
-60.7
|
-100.8
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-402.17%
|
-429.09%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-05
|
21-03-04
|
22-03-15
|
23-03-02
|
24-03-27
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5.697
|
7.802
|
5.467
|
6.276
|
3.891
|
-0.754
|
2.954
|
2.833
|
3.762
|
0.386
|
0.72
|
0.72
|
0.72
|
0.72
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.91
|
-25.42
|
-26.65
|
-33.77
|
-39.45
|
-36
|
-33.21
|
-34
|
-34.64
|
-27.14
|
-27.78
|
-29.12
|
-29.32
|
-32.85
|
-36
|
Operating Margin
|
-472.37%
|
-325.85%
|
-487.53%
|
-538.07%
|
-1,013.98%
|
4,774.14%
|
-1,124.31%
|
-1,200.14%
|
-920.68%
|
-7,031.09%
|
-3,857.64%
|
-4,045.14%
|
-4,072.92%
|
-4,562.5%
|
-
|
Earnings before Tax (EBT)
1 |
-26.03
|
-23.81
|
-25.15
|
-34.48
|
-30.25
|
-4.773
|
-23.79
|
-36.26
|
-40.14
|
-64.38
|
-29.76
|
-31.29
|
-31.65
|
-35.29
|
-36.48
|
Net income
1 |
-26.03
|
-23.81
|
-25.15
|
-34.48
|
-30.25
|
-4.773
|
-23.79
|
-36.26
|
-40.14
|
-64.38
|
-29.76
|
-31.29
|
-31.65
|
-35.29
|
-36.48
|
Net margin
|
-456.85%
|
-305.22%
|
-459.96%
|
-549.41%
|
-777.51%
|
633.02%
|
-805.31%
|
-1,279.84%
|
-1,067.07%
|
-16,679.79%
|
-4,133.68%
|
-4,346.35%
|
-4,395.83%
|
-4,901.04%
|
-
|
EPS
2 |
-4.100
|
-3.800
|
-4.000
|
-5.400
|
-3.210
|
-0.1700
|
-0.8500
|
-1.300
|
-1.430
|
-2.220
|
-0.8700
|
-0.9080
|
-0.9100
|
-1.000
|
-0.9200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-05
|
22-03-15
|
22-05-16
|
22-08-09
|
22-11-14
|
23-03-02
|
23-05-10
|
23-08-08
|
23-11-14
|
24-03-27
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
90.1
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-60.7
|
-101
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-99%
|
-102%
|
-88.9%
|
-
|
-
|
-
|
105%
|
ROA (Net income/ Total Assets)
|
-
|
-46.3%
|
-47.3%
|
-44.3%
|
-
|
-252%
|
-45.1%
|
-
|
Assets
1 |
-
|
181.6
|
182.9
|
213.7
|
-
|
49.53
|
266.3
|
-
|
Book Value Per Share
|
-
|
16.10
|
13.70
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-12.50
|
-15.20
|
-9.740
|
-
|
-3.010
|
-0.5500
|
1.980
|
Capex
|
-
|
3.34
|
1.25
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
22.1%
|
5.3%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-05
|
21-03-04
|
22-03-15
|
23-03-02
|
24-03-27
|
-
|
-
|
-
|
Average target price
19.25
USD Spread / Average Target +270.19% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.25% | 145M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|